KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS Q22*1
Panitumumab	Colon Mucinous Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID1131 A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC) PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC	civic
KRAS Amplification1
Carboplatin + Docetaxel + SorafenibCombination	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1497 Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC	civic
KRAS G12D4
Vemurafenib	Hairy Cell Leukemia	Predictive	C	Supports Resistance	2	accepted	EID1580 One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC	civic
Dabrafenib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID91 A 63 year old patient was diagnosed with lung adenocarcinoma and received several treatment regimens over approximately three years, including carboplatin/paclitaxel, erlotinib, pemetrexed/bevacizumab… (full text at CIViC) PMID 23524406 · Rudin et al., 2013 · Open in CIViC	civic
Dactolisib + SelumetinibCombination	Lung Adenocarcinoma	Predictive	D	Supports
KRAS RS617643701
Cisplatin	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	3	accepted	EID872 In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was adde… (full text at CIViC) PMID 25081901 · Chung et al., 2014 · Open in CIViC	civic
KRAS Mutation23
Refametinib + SorafenibCombination	Hepatocellular Carcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID1642 Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was per… (full text at CIViC) PMID 25294897 · Lim et al., 2014 · Open in CIViC	civic
Salirasib	Lung Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1218 In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival … (full text at CIViC) PMID 21847063 · Riely et al., 2011 · Open in CIViC	civic
Abemaciclib	Lung Non-Small Cell CarcinomaCURATED_BROADER
KRAS G12A1
Erlotinib + GefitinibSubstitutes	Lung Adenocarcinoma	Predictive	B	Supports Resistance	3	accepted	EID251 KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) wer… (full text at CIViC) PMID 19794967 · Marchetti et al., 2009 · Open in CIViC	civic
KRAS G12D + TSC1 Loss-of-functionKRAS TSC11
Sirolimus	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID154 Following rapamycin treatment of mice with KrasG12D-induced lung adenocarcinomas, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, i… (full text at CIViC) PMID 19966866 · Liang et al., 2010 · Open in CIViC	civic
KRAS A146V1
Abemaciclib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID794 Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led… (full text at CIViC) PMID 24836576 · Van Allen et al., 2014 · Open in CIViC	civic
KRAS G12C4
Divarasib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID11652 A phase 1 clinical study conducted with Divarasib in a total of 137 patients, of which 60 patients had NSCLC with G12C mutation in the KRAS gene. Confirmed response was noted in 53.4% (95% CI; 39.9 to… (full text at CIViC) PMID 37611121 · Sacher et al., 2023 · Open in CIViC	civic
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID1142 83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size a… (full text at CIViC) PMID 26125448 · Jänne et al., 2015 · Open in CIViC	civic
Sotorasib
KRAS G12V3
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	1	accepted	EID1143 83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 accordin… (full text at CIViC) PMID 26125448 · Jänne et al., 2015 · Open in CIViC	civic
Palbociclib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	1	accepted	EID795 In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treat… (full text at CIViC) PMID 20609353 · Puyol et al., 2010 · Open in CIViC	civic
Cetuximab
KRAS G12/G132
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID35 In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201). PMID 15696205 · Pao et al., 2005 · Open in CIViC	civic
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Resistance	3	accepted	EID6295 This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
KRAS G13D6
Pictilisib	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	4	accepted	EID2041 This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID306 KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS. PMID 20978259 · De Roock et al., 2010 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B
KRAS Exon 2 Mutation2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	A	Supports Resistance	5	accepted	EID993 KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone. 42% of… (full text at CIViC) PMID 18946061 · Karapetis et al., 2008 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID250 Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab. PMID 16618717 · Lièvre et al., 2006 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION USP (DIN 02361957) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 1, 2011	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177080) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 31, 2020	Dec 31, 1995	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177099) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,652)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 798 recruiting · 366 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1,551–1,600 of 1,652 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03351296	Two Chemotherapy Regimens Plus or Minus Bevacizumab(BETTER2)	active not recruiting	Phase 2	140	Gustave Roussy, Cancer Campus, Grand ParisOTHER	1	May 8, 2024	clinicaltrials
NCT05859217	A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)(Cabatezo-1)	not yet recruiting	Phase 2	40	Jun Zhang, MD, PhDOTHER	1	May 8, 2024	clinicaltrials
NCT05921149	Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer	not yet recruiting	N/A	170	Endeavor HealthOTHER	1	May 7, 2024	clinicaltrials
NCT06399926	Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir	recruiting	—	64	Xiangya Hospital of Central South UniversityOTHER	1	May 6, 2024	clinicaltrials
NCT06394713	A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors	not yet recruiting	Phase 1 / Phase 2	60	Qilu Pharmaceutical Co., Ltd.INDUSTRY	0	May 1, 2024	clinicaltrials
NCT03982485	Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer(APP)	active not recruiting	Phase 2	196	RenJi HospitalOTHER	1	Apr 30, 2024	clinicaltrials
NCT06300177	D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure	recruiting	Phase 3	522	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY	1	Apr 26, 2024	clinicaltrials
NCT03685890	Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion(NivoILP)	recruiting	Phase 1 / Phase 2	74	Vastra Gotaland RegionOTHER_GOV	2	Apr 25, 2024	clinicaltrials
NCT03767075	A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)(BoB)	recruiting	Phase 2	1,000	Vall d'Hebron Institute of OncologyOTHER	7	Apr 25, 2024	clinicaltrials
NCT06380348	JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations	not yet recruiting	Phase 3	398	Shanghai JMT-Bio Inc.INDUSTRY	0	Apr 23, 2024	clinicaltrials
NCT06373133	SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer	not yet recruiting	Phase 1 / Phase 2	36	West China HospitalOTHER	0	Apr 18, 2024	clinicaltrials
NCT02889666	A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer(CCODG-NSCLC)	recruiting	Phase 1	500	Shanghai Jiao Tong University School of MedicineOTHER	1	Apr 17, 2024	clinicaltrials
NCT06370754	Newly Emerging Immunotherapy for Pancreatic Cancer Treatment(FD-IMPACT)	not yet recruiting	Phase 1 / Phase 2	117	Fudan UniversityOTHER	1	Apr 17, 2024	clinicaltrials
NCT06366945	Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC	not yet recruiting	Phase 2	85	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	0	Apr 16, 2024	clinicaltrials
NCT05080556	Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv)	recruiting	Phase 2	80	University College, LondonOTHER	1	Apr 12, 2024	clinicaltrials
NCT06196788	Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer(PTCA199-9)	recruiting	Phase 2	30	Fudan UniversityOTHER	1	Mar 21, 2024	clinicaltrials
NCT06227117	Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer	recruiting	Phase 2	120	RemeGen Co., Ltd.INDUSTRY	1	Mar 19, 2024	clinicaltrials
NCT06259058	Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer	not yet recruiting	Phase 1 / Phase 2	96	Tianjin Medical University Cancer Institute and HospitalOTHER	0	Mar 15, 2024	clinicaltrials
NCT06202261	A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer	recruiting	Phase 1 / Phase 2	154	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY	1	Mar 12, 2024	clinicaltrials
NCT06307249	Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA)	recruiting	Phase 1	50	Lebanese UniversityOTHER	1	Mar 12, 2024	clinicaltrials
NCT06297811	Myeloprotection With Trilaciclib in Pan-cancer Population	not yet recruiting	Phase 2	132	Sun Yat-sen UniversityOTHER	1	Mar 7, 2024	clinicaltrials
NCT06299371	Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations	not yet recruiting	Phase 2	36	Liaoning Cancer Hospital & InstituteOTHER	0	Mar 7, 2024	clinicaltrials
NCT04300244	Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma(NIPU)	active not recruiting	Phase 2	118	Åslaug HellandOTHER	5	Feb 29, 2024	clinicaltrials
NCT05377658	AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer	recruiting	Phase 2	43	Henan Cancer HospitalOTHER_GOV	1	Feb 21, 2024	clinicaltrials
NCT06265350	Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases	recruiting	N/A	80	Sun Yat-sen UniversityOTHER	1	Feb 20, 2024	clinicaltrials
NCT06268652	Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer	recruiting	Phase 3	302	Sun Yat-sen UniversityOTHER	1	Feb 20, 2024	clinicaltrials
NCT05007132	Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer	recruiting	Phase 2	153	Dominik Paul ModestOTHER	1	Feb 15, 2024	clinicaltrials
NCT06254599	A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC	not yet recruiting	Phase 3	255	Shouyao Holdings (Beijing) Co. LTDOTHER	1	Feb 12, 2024	clinicaltrials
NCT05891093	Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)	recruiting	Phase 3	766	Fudan UniversityOTHER	1	Feb 8, 2024	clinicaltrials
NCT05983276	Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer	recruiting	Phase 2	40	Loyola UniversityOTHER	1	Feb 8, 2024	clinicaltrials
NCT03494946	Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer(SECAIII)	recruiting	N/A	30	Oslo University HospitalOTHER	1	Feb 6, 2024	clinicaltrials
NCT05159193	Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer	recruiting	Phase 3	372	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	1	Feb 2, 2024	clinicaltrials
NCT02641847	TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature	active not recruiting	Phase 2 / Phase 3	503	Fudan UniversityOTHER	1	Jan 25, 2024	clinicaltrials
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)(DRUP)	recruiting	Phase 2	1,550	The Netherlands Cancer InstituteOTHER	1	Jan 24, 2024	clinicaltrials
NCT06066216	Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer	not yet recruiting	Phase 2	45	Fujian Cancer HospitalOTHER_GOV	0	Jan 23, 2024	clinicaltrials
NCT06192680	Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer	not yet recruiting	Phase 2	63	Harbin Medical UniversityOTHER	0	Jan 18, 2024	clinicaltrials
NCT06210360	Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX	not yet recruiting	Phase 2	134	Changhai HospitalOTHER	0	Jan 18, 2024	clinicaltrials
NCT05011487	Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC(NOCE01)	recruiting	Phase 2	30	Sun Yat-sen UniversityOTHER	1	Jan 16, 2024	clinicaltrials
NCT06109402	Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer	not yet recruiting	Phase 2	160	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	Dec 19, 2023	clinicaltrials
NCT06159478	Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume)	recruiting	Phase 2	32	National Cancer Center, JapanOTHER_GOV	1	Dec 13, 2023	clinicaltrials
NCT06017284	Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer(PTCA199-5)	recruiting	Phase 3	100	Fudan UniversityOTHER	1	Nov 24, 2023	clinicaltrials
NCT06121700	Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G)	recruiting	Phase 2	55	Fudan UniversityOTHER	1	Nov 8, 2023	clinicaltrials
NCT06102395	Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC	recruiting	Phase 3	272	Beijing Tongren HospitalOTHER	1	Oct 30, 2023	clinicaltrials
NCT06102837	Tumor Vaccines for Solid Tumors	recruiting	—	340	Huashan HospitalOTHER	1	Oct 26, 2023	clinicaltrials
NCT04172259	ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC	active not recruiting	Phase 2	156	Sun Yat-sen UniversityOTHER	1	Oct 16, 2023	clinicaltrials
NCT06081673	Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC	recruiting	Phase 2	72	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER	1	Oct 13, 2023	clinicaltrials
NCT06076772	Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients	not yet recruiting	—	54	Assiut UniversityOTHER	1	Oct 11, 2023	clinicaltrials
NCT05777278	Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression	recruiting	Phase 1 / Phase 2	29	The First Affiliated Hospital of Guangzhou Medical UniversityOTHER	1	Oct 10, 2023	clinicaltrials
NCT06067776	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	not yet recruiting	Phase 1	36	Jonathan RiessOTHER	1	Oct 5, 2023	clinicaltrials
NCT06063070	First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer	not yet recruiting	Phase 2	44	Sun Yat-sen UniversityOTHER	1	Oct 2, 2023	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,652)

Linked publications (113)